Antipsychotic Adverse Events · Chapter 6 · Metabolic & Endocrine
Weight Gain & Metabolic Syndrome
Part 1 · Who's at Risk, and How Early You Can Tell
Nothing about this one demands attention in the moment. There's no spasm, no fever, no movement you can see across the room — just a patient who gains twenty pounds over a few months while everyone focuses on whether the psychosis is controlled. Yet people with schizophrenia die roughly 15 to 25 years earlier than the general population, with cardiovascular disease the leading cause, and metabolic syndrome affects around a third of this population. This half of the chapter is about seeing it coming. Part 2 is about what to do.
⏱ Bottom Line Up Front
- Antipsychotic weight gain is fastest and most decisive early — and there's a usable rule: >5% body weight gained in the first month predicts substantial long-term gain and should trigger escalation, not observation.
- Liability differs enormously by agent: chlorpromazine, clozapine and olanzapine highest, quetiapine/risperidone/paliperidone intermediate, ziprasidone/lurasidone/aripiprazole/cariprazine lowest in trial data. Important caveat: in antipsychotic-naïve and first-episode patients, the "low-risk" agents — aripiprazole especially — are not weight-neutral.
- Weight isn't a reliable proxy for metabolic harm. HbA1c rises across low-, moderate- and high-weight-gain agents alike, so glucose and lipids get tracked on their own schedule rather than inferred from the scale.
- Metabolic syndrome prevalence climbs fast — from about 22% at treatment initiation to 32% at one year. Youth gain two to three times what adults do and warrant the tightest attention.
- The whole chapter turns on the baseline you took and the visit you weighed at. Everything in Part 2 works better the earlier it starts.
📋 The Case
A 24-year-old man with a first episode of psychosis starts olanzapine. His symptoms respond beautifully — the team is pleased, and so is he. At the three-month visit he's gained 11 kg, his waist has expanded visibly, and his fasting glucose has drifted into the impaired range. Nobody weighed him between the start and now. He tells you, quietly, that he's thinking of stopping the medication because of how he looks. This is the moment the chapter is written for: the response is excellent, the metabolic cost is mounting fast, and the intervention window was three months ago.
🔍 Recognize
Antipsychotic-associated weight gain is driven largely by increased appetite and altered satiety — histamine H1 and serotonin 5-HT2C antagonism are the receptor actions most implicated — layered onto sedation, reduced activity, and the dietary and socioeconomic realities that often accompany serious mental illness. The result is not a slow drift: with the higher-liability agents, gain is most rapid in the initial weeks to months and then continues more gradually, which is why the early period carries such diagnostic and therapeutic weight.
Weight is only the visible part. The same agents drive insulin resistance, dyslipidemia, and hypertension — and the glycemic effects are not confined to the agents that cause the most weight gain. A 2025 meta-analysis found antipsychotics raise HbA1c relative to placebo across low-, moderate- and high-weight-gain agents alike, which is the clearest available evidence that a patient who hasn't gained dramatically is not automatically metabolically safe. That's why the monitoring schedule tracks glucose and lipids independently rather than using weight as a proxy.
One framing correction worth carrying: the drug amplifies a pre-existing vulnerability rather than creating it from nothing. About 22% of patients already meet metabolic syndrome criteria at treatment initiation — rising to 32% by one year — and more than 80% of people with psychosis are overweight or hypertensive at the time of diagnosis. That's an argument for baseline measurement and for treating cardiometabolic risk as core psychiatric care, not for excusing the drug's contribution.
Two populations deserve extra vigilance. Antipsychotic-naïve and first-episode patients gain the most steeply, and the differences between agents narrow considerably in this group. Children and adolescents are dramatically more susceptible — pediatric data show olanzapine producing gains in the range of 8–11 kg over months, and adolescents gaining roughly two to three times what adults do on the same agent.
Network meta-analysis finds that improvement in psychotic symptoms correlates with metabolic worsening — better symptom response tracks with greater increases in weight, BMI, and cholesterol. The patients doing best psychiatrically are often the ones paying the highest metabolic price. That isn't a reason to under-treat the illness; it's the reason metabolic prevention has to run alongside effective treatment rather than waiting for a problem to appear.
⏳ The Early Window
Early weight gain is the best available predictor of where a patient ends up — and it comes with a usable threshold. Gaining more than 5% of body weight in the first month predicts ≥15% gain by three months (sensitivity 67%, specificity 88%) and ≥20% gain by twelve months (sensitivity 47%, specificity 89%). The converse is the more useful half: of patients who stayed at or under 5% at one month, 97% remained moderate gainers at three months and 93% at twelve.
The specificity is what makes this usable: crossing 5% at one month rarely happens in someone who will stay stable. The practical consequence is to weigh at every visit in the early months and treat that line as a trigger to reconsider the agent, add a preventive intervention or escalate lifestyle support — not as something to note and revisit next quarter. Weight lost is far harder to reverse than weight prevented.
⚖️ Agent Liability — The Biggest Lever You Have
Antipsychotics differ more from each other on metabolic risk than on almost any other dimension, so agent selection does more work than any add-on. Figures below are approximate mean gain versus placebo over longer follow-up (median ~45 weeks), which better reflects real treatment durations than the 6-week trial figures usually quoted.
Chlorpromazine tops the list, ahead of clozapine — a reminder that first-generation agents are not the metabolically safe option they are sometimes assumed to be. Zotepine ranks similarly high where it is available.
| Tier | Agent | ~6 wks | ~45 wks |
|---|---|---|---|
| Highest | Chlorpromazine | — | +5.1 kg |
| Highest | Clozapine | +3.0 kg | +4.2 kg |
| Highest | Olanzapine | +2.8 kg | +3.8 kg |
| Intermediate | Risperidone / paliperidone | ~+1.4 kg | +1.6 to +2.1 kg |
| Intermediate | Quetiapine | +1.4 kg | +1.9 kg |
| Intermediate | Brexpiprazole | +1.3 kg | — |
| Lower | Cariprazine | +0.6 kg | — |
| Lower | Aripiprazole | +0.5 kg | +0.9 kg |
| Lower | Lurasidone | +0.4 kg | +0.6 kg |
| Lower | Ziprasidone | +0.2 kg | +0.3 kg |
The table above comes largely from trials in chronic, previously treated populations — and it can mislead when applied to a patient starting their first antipsychotic. In antipsychotic-naïve and first-episode patients the gaps narrow sharply. Head-to-head first-episode data put aripiprazole at roughly 9.2 kg at one year, not far behind risperidone's 10.5 kg.
A 2026 target-trial emulation in more than 60,000 patients went further, finding aripiprazole associated with greater six-month weight gain than olanzapine, quetiapine and risperidone. Read that one with its confounder attached: adherence to olanzapine was much lower than to aripiprazole (5–7% versus 15–21%), so some of the gap reflects who kept taking the drug rather than what the drug does.
Formulation matters here too — in early psychosis, oral aripiprazole has produced around 11 kg of gain versus roughly 3.7 kg for the long-acting injectable. The lesson isn't that the ranking is wrong; it's that metabolically "favorable" agents differ from the high-liability ones in pattern and speed as much as final magnitude. Monitor a first-episode patient on aripiprazole as attentively as one on olanzapine.
An emerging option: xanomeline–trospium, the first antipsychotic acting through muscarinic agonism rather than D2 blockade, has a fundamentally different metabolic profile — trial data show reduced risk of ≥7% weight gain versus placebo and favorable lipid changes. Long-term real-world data are still limited, but it's worth knowing about for patients in whom metabolic risk dominates the choice of agent.
Note the tension all this creates: clozapine is the most effective agent for treatment-resistant illness and olanzapine among the most effective overall, yet both sit near the top of the metabolic risk list. The answer is rarely to avoid them — it's to use them with prevention built in, which is where Part 2 begins.
Does the Dose Change the Weight Risk?
Sabé M, Pallis K, Solmi M, Crippa A, Sentissi O, Kaiser S. Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis. J Clin Psychiatry. 2023 Feb 8;84(2):22r14490. PMID 36752753
Questions this discussion answers
- Which antipsychotics carry the lowest and highest risk of weight gain.
- Which agents show lower weight-gain risk at high doses.
- Which agents show a weight-gain risk that plateaus at high doses.
- Which agents show higher weight-gain risk at high doses.
- Quetiapine XR versus IR: weight gain and metabolic parameters compared.
- Whether long-acting injectables differ from oral agents in weight-gain risk.
Why it sits here: the chart and table above are agent-level and dose-blind, which is how most liability rankings are presented — and that quietly assumes risk scales the same way for every drug. It doesn't. Pairing this with the efficacy dose-response literature gives the practical rule: once an agent is at the dose where symptom benefit has largely flattened, further increases can keep buying weight without buying response.
Does Switching Actually Take the Weight Off?
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014 Apr 24;9(4):e94112. PMID 24763306
Questions this discussion answers
- Do all antipsychotics produce a mean weight increase as duration of use lengthens?
- Which agent and which time period show the most significant gain?
- Which agents showed no statistically significant weight change from baseline?
- Does switching to a "weight-neutral" antipsychotic actually produce weight loss?
- How does weight gain behave in antipsychotic-naïve patients?
- Which factors matter most when weighing antipsychotic-related weight gain?
Why it sits here: this is the natural-history paper behind everything above — how much weight, on which agent, over what duration, and in whom. Its answer to the switching question points forward to Part 2, and is more sobering than most clinicians expect. On currency: the agent-level magnitudes are now better read from the network meta-analyses cited in this chapter, but the paper's core teaching points have since been extended rather than overturned by the same group — first to naïve-versus-switch populations (Bak 2021), then to clinically relevant ≥7% change, where longer exposure was associated with more clinically relevant gain even on the metabolically friendlier agents (Campforts 2023).
📐 Defining Metabolic Syndrome
Metabolic syndrome isn't a separate disease so much as a cluster that marks cardiovascular and diabetes risk. The widely used criteria require three or more of the following — worth knowing precisely, because it converts a vague sense of "he's gained weight" into a documentable diagnosis that justifies intervention.
Waist
≥102 cm men
≥88 cm women
Triglycerides
≥150 mg/dL
or on treatment
HDL
<40 men
<50 women mg/dL
Blood pressure
≥130/85 mmHg
or on treatment
Fasting glucose
≥100 mg/dL
or on treatment
Waist thresholds are the ATP III/AHA values; lower cut-points apply in some populations (IDF: ≥90 cm Asian men, ≥80 cm Asian women). Any three of the five establishes the diagnosis.
Waist circumference deserves a specific mention: it's cheap, fast, and often more informative than BMI for this population — and it's the measure most likely to be skipped. Which points at the real problem: guideline monitoring schedules are clear, but real-world screening rates fall well short of them. The gap isn't knowledge, it's execution — which makes the habit, not the schedule, the thing worth building.
🗓 The Monitoring Schedule
The consensus schedule below is the one the habit should be built around. Print it, or build it into your template — the whole point is that it stops being a decision each visit.
| Measure | Baseline | 4 wks | 8 wks | 12 wks | Then |
|---|---|---|---|---|---|
| Weight / BMI | ✓ | ✓ | ✓ | ✓ | Quarterly |
| Waist circumference | ✓ | — | — | — | Annually |
| Blood pressure | ✓ | — | — | ✓ | Annually |
| Fasting glucose / HbA1c | ✓ | — | — | ✓ | Annually |
| Fasting lipids | ✓ | — | — | ✓ | Annually |
Weigh more often than this in the first three months if the agent is high-liability or the patient is antipsychotic-naïve — the one-month reading is the one that changes decisions, and it only works if someone takes it.
🪜 The Action Ladder — Part 1
- Choose the agent deliberatelyWhere efficacy allows, start with a lower-liability agent — especially in antipsychotic-naïve patients, youth, and anyone with baseline metabolic risk. This decision outweighs everything that follows.
- Baseline before you startWeight/BMI, waist, BP, fasting glucose/HbA1c, lipids, family history. The baseline you skip is the one you'll wish you had.
- Weigh early and oftenEvery visit in the first months. Crossing 5% gain at one month is the trigger to act, not a note to revisit later.
- Screen the rest of the cluster on scheduleGlucose, lipids, blood pressure and waist per the table above — independently of what the scale is doing.
- Stage itCount the metabolic syndrome criteria. Three of five converts a vague impression into a documented diagnosis that justifies intervention.
- Act on what you findPrevention and treatment are Part 2 — but the trigger to open it is anything above.
- >5% at one month is your decision rule. It predicts ≥15% gain at three months and ≥20% at twelve — escalate there rather than at the annual review.
- Agent choice beats every add-on — but "low-risk" isn't weight-neutral. In first-episode patients aripiprazole has produced ~9.2 kg at one year; monitor accordingly.
- Chlorpromazine, not clozapine, tops the liability list. First-generation agents are not the metabolically safe alternative.
- Formulation matters — oral aripiprazole produced roughly 11 kg in early psychosis versus 3.7 kg for the long-acting injectable.
- The best responders often gain the most. Symptom improvement correlates with metabolic worsening, so prevention has to run alongside effective treatment.
- Weight isn't a reliable proxy for metabolic harm. HbA1c rises even on the low-weight-gain agents — measure glucose and lipids separately.
- Waist circumference is the underused measure — ≥102 cm men, ≥88 cm women; cheap, quick, more informative than BMI here.
- Youth gain two to three times what adults do. Tighten monitoring and lower the threshold for prevention.
- This is an adherence issue as much as a medical one. Weight gain is a leading reason patients quit effective treatment — raise it before they do.
- Rapid gain in the first weeks of a high-liability agent with no preventive plan in place.
- Symptoms of hyperglycemia — thirst, polyuria, blurred vision, unexplained weight loss — which warrant urgent glucose testing (see New-Onset Diabetes & Hyperglycemia; diabetic ketoacidosis can occur).
- A patient hinting they may stop the medication because of their weight — an adherence emergency in slow motion.
- Months or years on an antipsychotic with no metabolic bloodwork on record.
- Weight gain dismissed as "lifestyle" without reviewing the drug's contribution.
"This medication can increase appetite and cause weight gain, and I'd rather plan for that with you now than have it surprise you. The first few months matter most, so I'll check your weight at each visit and run some bloodwork to keep an eye on sugar and cholesterol. We'll put support in place from the start, and there are medications that genuinely help limit the gain if we need them. If the weight starts bothering you, please tell me before you stop taking this — there are usually options, including switching to a medication that's easier on weight, and stopping suddenly is the bigger risk."
You've found it early. Now what?
Part 1 gets you to the decision point: you know who's at risk, you have the one-month rule, and you have a monitoring schedule that works. Part 2 is everything that happens next — metformin co-commencement and the dose, monitoring and stopping rules behind it; where GLP-1 receptor agonists now sit and what they actually deliver; when switching helps and when it doesn't; and a full masterclass on weight-loss pharmacology. The complete Antipsychotics course carries the rest of the metabolic picture, plus the cardiac, prolactin, and clozapine-specific events behind daily prescribing.
Unlock Part 2 and the full course →References
- Vandenberghe F, Najar-Giroud A, Holzer L, Conus P, Eap CB, Ambresin AE. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. J Child Adolesc Psychopharmacol. 2018;28(4):258–265 — the >5% at one month threshold and its operating characteristics.
- Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function: systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77 — short-term agent ranking; correlation between symptom improvement and metabolic worsening.
- Burschinski A, Schneider-Thoma J, Chiocchia V, et al. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment: network meta-analysis. World Psychiatry. 2023;22(1):116–128 — ~45-week weight-gain figures, including chlorpromazine and zotepine.
- Sabé M, Pallis K, Solmi M, Crippa A, Sentissi O, Kaiser S. Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis. J Clin Psychiatry. 2023;84(2):22r14490 — dose-response behaviour, formulation and LAI comparisons (embedded journal club).
- Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112 — duration-stratified weight change (embedded journal club).
- Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis. PLoS One. 2021;16(2):e0244944.
- Campforts B, Drukker M, Crins J, van Amelsvoort T, Bak M. Association between antipsychotic medication and clinically relevant weight change: meta-analysis. BJPsych Open. 2023;9(1):e18 — clinically relevant (≥7%) gain and loss, stratified by exposure duration.
- Antipsychotic drugs and dysregulated glucose homeostasis: systematic review and meta-analysis. JAMA Psychiatry. 2025 — HbA1c rises versus placebo across low-, moderate- and high-weight-gain agents.
- Petimar J, et al. Comparative effectiveness of antipsychotics on six-month weight change: target trial emulation. 2026 — aripiprazole versus olanzapine, quetiapine and risperidone in >60,000 patients, with differential adherence as a stated limitation.
- Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness — state-of-the-art reviews covering the mortality gap, cardiovascular disease as leading cause, and baseline overweight and hypertension burden at diagnosis.
- American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601 — the monitoring schedule reproduced above.
- Keepers GA, Casey DE, Daniel DG, et al. The APA Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020;177(9):868–872 (executive summary) — monitoring and metabolic management.
Responses